Eir-060 Product Launch

EirGen Pharma are delighted to announce that our product EIR-060 has launched in the United States. EIR-060 is indicated for the treatment of various forms of brain tumours and is a significant launch for EirGen who have commercialised this product in many EU territories already. The market size in terms of annual sales of the product in the US was over $80M to end of Q1 2018.